Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial Albumin with Endovascular Treatment for Acute Ischemic Stroke
NCT06172387Phase 1Active, not recruiting
- Sponsor
- Tianjin Huanhu Hospital
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of albumin (human) in ischemic stroke, sponsored by Tianjin Huanhu Hospital. Primary endpoint: cerebral infarct volume. Started Nov 2023; status: active, not recruiting.
02
Drugs
albumin (human)
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06172387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06172387.